Rosalind Advisors, Inc.
•CIK: 1622627•Filing: Q4 2025
**Rosalind Advisors, Inc.** manages $285M across a concentrated portfolio of 39 positions. The fund exhibits significant exposure to key names, notably maintaining a substantial allocation to DCTH at $33.0M. Further top holdings include YB4P ($20.5M), FRX ($20.1M), and XERS ($16.6M), indicating targeted, high-conviction bets within its investment mandate. This structure suggests a focused, tactical approach to capital deployment.
Total AUM
$274.5M
+ $10.1M in options
QoQ Performance
-3.0%
Positions
29
+ 10 options
Top 10 Concentration
60.7%
Latest Filing
Q4 2025
Top Holdings Allocation
DCTH
YB4P
FRX
XERS
DCTH11.6%
YB4P7.2%
FRX7.1%
XERS5.8%
VRDN4.9%
MEDIWOUND4.9%
VSTM4.9%
REPL4.8%
📈 Biggest Buys
📉 Biggest Sells
Sector Breakdown
Other99.3%
ETF0.7%
🚪 Exited Positionssold since Q3 2025
—
ATYR PHARMA INC
SOLD
$4.5M
+4 more exited positions
Changes from Q3 2025
NEW9 new positions
↑9 increased
↓10 decreased
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023